278 related articles for article (PubMed ID: 24912192)
1. PHLDA3 is a novel tumor suppressor of pancreatic neuroendocrine tumors.
Ohki R; Saito K; Chen Y; Kawase T; Hiraoka N; Saigawa R; Minegishi M; Aita Y; Yanai G; Shimizu H; Yachida S; Sakata N; Doi R; Kosuge T; Shimada K; Tycko B; Tsukada T; Kanai Y; Sumi S; Namiki H; Taya Y; Shibata T; Nakagama H
Proc Natl Acad Sci U S A; 2014 Jun; 111(23):E2404-13. PubMed ID: 24912192
[TBL] [Abstract][Full Text] [Related]
2. Pancreatic Neuroendocrine Tumors in Mice Deficient in Proglucagon-Derived Peptides.
Takano Y; Kasai K; Takagishi Y; Kikumori T; Imai T; Murata Y; Hayashi Y
PLoS One; 2015; 10(7):e0133812. PubMed ID: 26192435
[TBL] [Abstract][Full Text] [Related]
3. A review of functional pancreatic neuroendocrine tumors: Exploring the molecular pathogenesis, diagnosis and treatment.
Alshareefy Y; Cummins S; Mazzoleni A; Sharma V; Guggilapu S; Leong AWY; Wireko AA
Medicine (Baltimore); 2023 Nov; 102(46):e36094. PubMed ID: 37986400
[TBL] [Abstract][Full Text] [Related]
4. Epigenetic landscape of pancreatic neuroendocrine tumours reveals distinct cells of origin and means of tumour progression.
Di Domenico A; Pipinikas CP; Maire RS; Bräutigam K; Simillion C; Dettmer MS; Vassella E; Thirlwell C; Perren A; Marinoni I
Commun Biol; 2020 Dec; 3(1):740. PubMed ID: 33288854
[TBL] [Abstract][Full Text] [Related]
5. Combined deletion of MEN1, ATRX and PTEN triggers development of high-grade pancreatic neuroendocrine tumors in mice.
Fuentes ME; Lu X; Flores NM; Hausmann S; Mazur PK
Sci Rep; 2024 Apr; 14(1):8510. PubMed ID: 38609433
[TBL] [Abstract][Full Text] [Related]
6. Angiopoietin-2 blockade suppresses growth of liver metastases from pancreatic neuroendocrine tumors by promoting T cell recruitment.
Lee E; O'Keefe S; Leong A; Park HR; Varadarajan J; Chowdhury S; Hiner S; Kim S; Shiva A; Friedman RA; Remotti H; Fojo T; Yang HW; Thurston G; Kim M
J Clin Invest; 2023 Oct; 133(20):. PubMed ID: 37843277
[TBL] [Abstract][Full Text] [Related]
7. Characterizing the role of Phlda3 in the development of acute toxicity and malignant transformation of hematopoietic cells induced by total-body irradiation in mice.
Hasapis S; Caraballo I; Sears TJ; Brock KD; Cart JB; Moding EJ; Lee CL
Sci Rep; 2023 Aug; 13(1):12916. PubMed ID: 37558703
[TBL] [Abstract][Full Text] [Related]
8. Daxx maintains endogenous retroviral silencing and restricts cellular plasticity in vivo.
Wasylishen AR; Sun C; Moyer SM; Qi Y; Chau GP; Aryal NK; McAllister F; Kim MP; Barton MC; Estrella JS; Su X; Lozano G
Sci Adv; 2020 Aug; 6(32):eaba8415. PubMed ID: 32821827
[TBL] [Abstract][Full Text] [Related]
9. Altered CELF4 splicing factor enhances pancreatic neuroendocrine tumors aggressiveness influencing mTOR and everolimus response.
Alors-Pérez E; Pedraza-Arevalo S; Blázquez-Encinas R; García-Vioque V; Agraz-Doblas A; Yubero-Serrano EM; Sánchez-Frías ME; Serrano-Blanch R; Gálvez-Moreno MÁ; Gracia-Navarro F; Gahete MD; Arjona-Sánchez Á; Luque RM; Ibáñez-Costa A; Castaño JP
Mol Ther Nucleic Acids; 2024 Mar; 35(1):102090. PubMed ID: 38187140
[TBL] [Abstract][Full Text] [Related]
10. Cancer Cells Retrace a Stepwise Differentiation Program during Malignant Progression.
Saghafinia S; Homicsko K; Di Domenico A; Wullschleger S; Perren A; Marinoni I; Ciriello G; Michael IP; Hanahan D
Cancer Discov; 2021 Oct; 11(10):2638-2657. PubMed ID: 33910926
[TBL] [Abstract][Full Text] [Related]
11. A vicious partnership between AKT and PHLDA3 to facilitate neuroendocrine tumors.
Takikawa M; Ohki R
Cancer Sci; 2017 Jun; 108(6):1101-1108. PubMed ID: 28295876
[TBL] [Abstract][Full Text] [Related]
12. Combination of antiangiogenic therapy using the mTOR-inhibitor everolimus and low-dose chemotherapy for locally advanced and/or metastatic pancreatic cancer: a dose-finding study.
Joka M; Boeck S; Zech CJ; Seufferlein T; Wichert Gv; Licht T; Krause A; Jauch KW; Heinemann V; Bruns CJ
Anticancer Drugs; 2014 Oct; 25(9):1095-101. PubMed ID: 25029236
[TBL] [Abstract][Full Text] [Related]
13. Gly388Arg FGFR4 Polymorphism Is Not Predictive of Everolimus Efficacy in Well-Differentiated Digestive Neuroendocrine Tumors.
Cros J; Moati E; Raffenne J; Hentic O; Svrcek M; de Mestier L; Sbidian E; Guedj N; Bedossa P; Paradis V; Sauvanet A; Panis Y; Ruszniewski P; Couvelard A; Hammel P
Neuroendocrinology; 2016; 103(5):495-9. PubMed ID: 26335532
[TBL] [Abstract][Full Text] [Related]
14. Beneficial Effects of the mTOR Inhibitor Everolimus in Patients with Advanced Medullary Thyroid Carcinoma: Subgroup Results of a Phase II Trial.
Schneider TC; de Wit D; Links TP; van Erp NP; van der Hoeven JJ; Gelderblom H; van Wezel T; van Eijk R; Morreau H; Guchelaar HJ; Kapiteijn E
Int J Endocrinol; 2015; 2015():348124. PubMed ID: 26294908
[TBL] [Abstract][Full Text] [Related]
15. Symptomatic Control of Neuroendocrine Tumours with Everolimus.
Bainbridge HE; Larbi E; Middleton G
Horm Cancer; 2015 Dec; 6(5-6):254-9. PubMed ID: 26245686
[TBL] [Abstract][Full Text] [Related]
16. NeuroEndocrine Tumor Therapy with Lutetium-177-octreotate and Everolimus (NETTLE): A Phase I Study.
Claringbold PG; Turner JH
Cancer Biother Radiopharm; 2015 Aug; 30(6):261-9. PubMed ID: 26181854
[TBL] [Abstract][Full Text] [Related]
17. Mutation-targeted therapy with sunitinib or everolimus in patients with advanced low-grade or intermediate-grade neuroendocrine tumours of the gastrointestinal tract and pancreas with or without cytoreductive surgery: protocol for a phase II clinical trial.
Neychev V; Steinberg SM; Cottle-Delisle C; Merkel R; Nilubol N; Yao J; Meltzer P; Pacak K; Marx S; Kebebew E
BMJ Open; 2015 May; 5(5):e008248. PubMed ID: 25991462
[TBL] [Abstract][Full Text] [Related]
18. Control of the MYC-eIF4E axis plus mTOR inhibitor treatment in small cell lung cancer.
Matsumoto M; Seike M; Noro R; Soeno C; Sugano T; Takeuchi S; Miyanaga A; Kitamura K; Kubota K; Gemma A
BMC Cancer; 2015 Apr; 15():241. PubMed ID: 25884680
[TBL] [Abstract][Full Text] [Related]
19. Impact of Previous Somatostatin Analogue Use on the Activity of Everolimus in Patients with Advanced Neuroendocrine Tumors: Analysis from the Phase III RADIANT-2 Trial.
Anthony LB; Pavel ME; Hainsworth JD; Kvols LK; Segal S; Hörsch D; Van Cutsem E; Öberg K; Yao JC
Neuroendocrinology; 2015; 102(1-2):18-25. PubMed ID: 25824001
[TBL] [Abstract][Full Text] [Related]
20. Long-term everolimus treatment of patients with pancreatic neuroendocrine tumors.
Wolin EM
Chemotherapy; 2014; 60(3):143-50. PubMed ID: 25766415
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]